Private Market View

Bionaute (Biotechnology)

Santiago, Chile · Founded 2023 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$400K
Last round

Key facts

  • It has raised $400K; the latest was Seed Round ($400K) in Mar 2026.
  • Notable investors include KunzA.I Ventures.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 1 names
  • ·Watchlist + deal alerts for Bionaute (Biotechnology)
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Bionaute (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Bionaute (Biotechnology)

Developer of RNAi-based biopesticides intended to enable sustainable crop protection. The company designs AI-driven RNA molecules that silence essential genes in pests and pathogens, leveraging natural plant defense mechanisms to create residue-free, ecosystem-safe solutions, enabling farmers to protect crops from insects, fungi, viruses, and weeds while supporting environmentally responsible agriculture.

Sector
Materials and Resources
HQ
Santiago, Chile
Founded
2023
Employees
5
Ownership
Privately Held (backing)
PA Mark — not yet priced

Bionaute (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Bionaute (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Bionaute (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.